On October 23, 2026, a clinical trial update was recorded for synthetic angiotensin II, marketed as Giapreza, in pediatric patients with refractory hypotension. The study, registered as NCT07212686, is titled "Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension." It is listed as a Phase 4 trial. The current status is enrolling by invitation, meaning participants are being recruited through direct invitation rather than open enrollment. No results have been posted for this trial as of this update. Angiotensin II is an approved compound, and this Phase 4 study represents further evaluation of its use in a pediatric population experiencing refractory hypotension. Phase 4 trials typically occur after a drug has received regulatory approval and are used to gather additional data in specific populations or settings. This update reflects only the trial's enrollment status and does not include outcome or efficacy data. Readers interested in additional background on this compound can consult the compound overview for further context.
Phase 4 Trial of Angiotensin II (Giapreza) in Pediatric Hypotension Updated
See the full angiotensin ii overview
Source: https://clinicaltrials.gov/study/NCT07212686